Thrombophilic state in breast cancer

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 2, 1999, Pages 157-166

  Schmitt, Manfred ^a,b   Kuhn, Walther ^a   Harbeck, Nadia ^a   Graeff, Henner ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Breast cancer; Chemotherapy; Coagulation; Hemostasis; Hormone therapy; Thromboembolism; Thrombosis

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; FADROZOLE; FLUOROURACIL; GOSERELIN; LETROZOLE; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; PACLITAXEL; RALOXIFENE; TOREMIFENE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; DISEASE ASSOCIATION; DRUG CHOICE; DRUG SAFETY; HUMAN; HYPERCOAGULABILITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOGENESIS; THROMBOSIS;

EID: 0032934697     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994917     Document Type: Review

References (94)

1. Agnelli G. Venous thromboembolism and cancer: A two-way clinical association. Thromb Haemost 1997;78:117-120
2. Naschitz JE, Yeshurun D, Eldar S, Lev LM. Diagnosis of cancer-associated vascular disorders. Cancer 1996;77:1759-1767
3. Costantini V, de Monte P, Cozzato AO, et al. Systemic thrombin generation in cancer patients is correlated with extrinsic pathway activation. Blood Coag Fibrinolysis 1998;9:79-84
4. Donati MB. Cancer and thrombosis. Haemostasis 1994;24: 128-131
5. Falanga A, Barbui T, Rickles FR, Levine MN. Hemostatic alterations in cancer patients. Thromb Haemost 1993;70:540-542
6. Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990;17:147-159
7. Piccioli A, Prandoni P, Ewenstein BM, Goldhaber SZ. Cancer and venous thromboembolism. Am Heart J 1996;132:850-855
8. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992;11:237-248
9. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Cancer Metastasis Rev 1992;11:237-248
10. Patterson WP, Ringenberg QS. The pathophysiology of thrombosis in cancer. Semin Oncol 1990;17:140-146
11. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five drug chemotherapy regimen. Cancer 1984;54:1264-1268
12. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997;78: 133-136
13. Grignani G, Falanga A, Pacchiarini L, et al. Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties. Int J Cancer 1988;42:554-557
14. Shoji M, Hancock WW, Abe K, et al. Activation of coagulation and angiogenesis in cancer: Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998;152:399-411
15. Edwards RL, Silver J, Rickles FR (for the Subcommittee). Human tumor procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb Haemost 1993;69:205-213
16. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995;346:1004-1005
17. Ozyilkan O, Baltali E, Ozdemir O, et al. Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin complex and thrombin-antithrombin III complex in female breast cancer. Tumori 1998;84:364-367
18. Zhou JN, Ljungdahl S, Shoshan MC, Swedenborg J, Linder S. Activation of tissue-factor gene expression in breast carcinoma cells by stimulation of the RAF-ERK signaling pathway. Mol Carcinog 1998;21:234-243
19. Reitsma PH. Protein C deficiency: From gene defects to disease. Thromb Haemost 1997;78:344-350
20. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993;72:477-480
21. Hooper WC, Evatt BL. The role of activated protein C resistance in the pathogenesis of venous thrombosis. Am J Med Sci 1998;316:120-128
22. Bayston TA, Lane DA. Antitrombin: Molecular basis of deficiency. Thromb Haemost 1997;78:339-343
23. Green D, Maliekel K, Sushko E, Akhtar R, Soff GA. Activated-protein-C resistance in cancer patients. Haemostasis 1997;27: 112-118
24. Rosing J, Tans G. Coagulation factor V: An old star shines again. Thromb Haemost 1997;78:427-433
25. Ohlin AK, Norlund I., Marlar RA. Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost 1997;78: 396-400
26. Sallah S. Inhibitors to clotting factors. Ann Hematol 1997;75:1-77
27. Ruffatti A, Aversa S, Del Ross T, et al. Antiphospholipid antibody syndrome associated with ovarian cancer. A new paraneoplastic syndrome? J Rheumatol 1994;21:2162-2163
28. Carhuapoma JR, Mitsias P, Levine SR. Cerebral venous thrombosis and anticardiolipin antibodies. Stroke 1997;28:2363-2369
29. Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost 1997;78:141-144
30. Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep vein thrombosis after major gynaecological surgery using labelled fibrinogen phlebography and lung scanning. J Obstet Gynaecol Br Commonw 1974;8:311-316
31. Prandoni P, Lesing AWA, Büller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445
32. Green D, Hall RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992;339:1476
33. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with intravenous standard heparin in proximal deep-vein thrombosis. N Engl J Med 1992;326:975-982
34. Pengo V, Zasso A, Barbero F, Garelli E, Biasiolo A. Low intensity warfarin therapy. Haematologica 1997;82:710-712
35. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-889
36. Falanga A, Levine MN, Consonni R, et al. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial. Thromb Haemost 1998;79:23-27
37. Trousseau A. Phlegmasia alba dolens. Clinique médicale de l'Hôtel de Dieu de Paris. London: New Sydenham Society 1865;3:695-727
38. Wall JG, Weiss RB, Norton L, et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: A Cancer and Leukemia Group B Study. Am J Med 1989;87:501-504
39. Osborne CK, Clark GM, Ravdin PM. Adjuvant systemic therapy of primary breast cancer. In: Harris JR, Morrow M, Lippman ME, Hellman S, eds. Diseases of the Breast. Philadelphia: Lippincott-Raven Publishers, 1996:548-578
40. Honig SF. Hormonal therapy and chemotherapy. In: Harris JR. Morrow M, Lippman ME, Hellman S, eds. Diseases of the Breast. Philadelphia: Lippincott-Raven Publishers, 1996:669-734
41. Doll DC, Yarbro JW. Vascular toxicity associated with antineoplastic agents. Semin Oncol 1992;19:580-596
42. von Tempelhoff GF, Dietrich M, Hommel G, Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol 1996;14:2560-2568
43. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-294
44. Oberhoff C, Winkler UH, Tauchert AM, Schindler AE. Adjuvant CMF chemotherapy in patients with breast cancer - results on blood coagulation and fibrinolysis. Zentralbl Gynäkol 1997;119:211-217
45. Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 1989;63:1303-1307
46. Huan S, Pazdur R, Singhakowinta A, Samal B, Vaitkevicius VK. Low-dose continuous infusion of 5-fluorouracil. Evaluation in advanced breast carcinoma. Cancer 1989;63:419-422
47. Bertomeu MC, Gallo S, Lauri D, et al. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis 1990;8:511-518
48. O'Reilly SE, Gelmon KA, Onetto N, et al. Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. J Clin Oncol 1993;11:2411-2416
49. Tolcher AW, Giusti RM, O'Shaughnessy JA, Cowan KH. Arterial thrombosis associated with granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in breast cancer patients treated with dose-intensive chemotherapy: A report of two cases. Cancer Invest 1995;13:188-192
50. Eisen T, Smith IE, Johnston S, et al. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol 1998;16:1350-1357
51. Theodossiou C, Kroog G, Ettinghausen S, et al. Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5-fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin-3. Cancer 1994;74:2808-2810
52. Sevelda P, Mayerhofer K, Obermair A, Stolzlechner J, Kurz C. Thrombosis with paclitaxel. Lancet 1994;343:727
53. Vogel CL. Hormonal approaches to breast cancer treatment and prevention: An overview. Semin Oncol 1996;4 Suppl 9:2-9
54. Buzdar A. The place of chemotherapy in the treatment of early breast cancer. Br J Cancer 1998;78 Suppl 4:16-20
55. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res 1998;4:527-534
56. Jordan VC. Preventing breast cancer with tamoxifen. Hosp Pract (Off Ed) 1998;33:59-64, 67-68, 71-72
57. Powles TJ. Status of antiestrogen breast cancer prevention trials. Oncology (Huntingt) 1998;12 (Suppl 5):28-31
58. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388
59. Mannucci PM, Bettega D, Chantarangkul V, et al. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 1996;156:1806-1810
60. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-97
61. Decensi A, Robertson C, Rotmensz N, et al. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group. Br J Cancer 1998;78:572-578
62. Cattaneo M, Baglietto L, Zighetti ML, et al. Tamoxifen reduces plasma homocysteine levels in healthy women. Br J Cancer 1998;77:2264-2266
63. Jones AL, Powles TJ, Treleaven JG, et al. Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Br J Cancer 1992;66:744-747
64. Mamby CC, Love RR, Feyzi JM. Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women. Breast Cancer Res Treat 1994;30:311-314
65. Love RR, Surawicz TS, Williams EC. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med 1992;152:317-320
66. Pemberton KD, Melissari E, Kakkar VV. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coag Fibrinolysis 1993;4:935-942
67. Jankowski J, Ramlau C, Kopczynski Z, Boryska M. The influence of tamoxifen on plasma coagulation and serous fibrinolysis. Eur J Gynaecol Oncol 1993;14 Suppl:155-158
68. Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1997;79:2024-2027
69. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998;45:608-612
70. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 1995;311:977-980
71. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-1542
72. Cutuli B, Petit JC, Fricker JP, et al. Thromboembolic accidents in postmenopausal patients with adjuvant treatment by tamoxifen. Frequency, risk factors and prevention possibilities. Cancer 1995;82:51-56
73. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 1998;16:2018-2024
74. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993; 85:1398-1406
75. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anti-cancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-407
76. Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996;14: 2731-2737
77. Deshmukh N, Tripathi SP. Thrombosis of tibial arteries in a patient receiving tamoxifen therapy. Cancer 1995;76:1006-1008
78. Vogel CL. Phase II and III clinical trials of toremifene for metastatic breast cancer. Oncology (Huntingt) 1998;12(Suppl 5):9-13
79. Maenpaa JU, Ala-Fossi SL. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost. Drugs Aging 1997;11:261-270
80. Holli K. Adjuvant trials of toremifene vs tamoxifen: The European experience. Oncology (Huntingt) 1998;12(Suppl 5):23-27
81. Winkler UH, Lauck US, Ebert C, Schindler AE. The effect of cyclic administration of progestagens on blood coagulation factors. Zentralbl Gynäkol 1998;120:32-37
82. Ishizaki T, Itoh R, Yasuda J, Yamamoto T, Okada H. Effect of high-dose medroxyprogesterone acetate on coagulative and fibrinolytic factors in patients with gynecological cancers. Gan To Kagaku Ryoho 1992;19:837-842
83. Yamamoto H, Noguchi S, Miyauchi K, et al. Changes in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer. Jpn J Cancer Res 1991;82:420-425
84. Nakagawa T, Yasuno M, Tanahashi H, et al. A case of acute myocardial infarction. Intracoronary thrombosis in two major coronary arteries due to hormone therapy. Angiology 1994;45:333-338
85. Koyama H, Nishizawa Y, Noguchi S, et al. Combination therapy with 5'DFUR and MPA as a second line treatment for advanced/recurrent breast cancer. Nippon Gan Chiryo Gakkai Shi 1990;25:655-661
86. Abe O, Asaishi K, Izuo M, et al. Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system. Surg Today 1995;25:701-710
87. Harvey HA. Emerging role of aromatase inhibitors in the treatment of breast cancer. Oncology (Huntingt) 1998;12(Suppl 5): 32-53
88. Thurlimann B, Castiglione M, Hsu-Schmitz SF, et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research. Eur J Cancer 1997;33:1017-1024
89. Thurlimann B, Beretta K, Bacchi M, et al. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 1996;7:471-479
90. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators. Horm Res 1997;48:155-163
91. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-1451
92. Delmas PD, Mitlak BH, Christiansen C. Authors reply to: Effects of raloxifene in postmenopausal women by Cole RC et al. N Engl J Med 1998;338:1313-1314
93. Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocr Rev 1990;11:221-265
94. Lindoff C, Petersson F, Samsioe G, Astedt B. Treatment with a GnRH analogue: Effects on hemostatic risk factors for thromboembolic disease. Int J Fertil Menopausal Stud 1994;39:133-139